These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 24387664)

  • 1. Update of cetuximab for non-melanoma skin cancer.
    Wollina U
    Expert Opin Biol Ther; 2014 Feb; 14(2):271-6. PubMed ID: 24387664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cetuximab in non-melanoma skin cancer.
    Wollina U
    Expert Opin Biol Ther; 2012 Jul; 12(7):949-56. PubMed ID: 22519406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chimeric Monoclonal Antibody Cetuximab Targeting Epidermal Growth Factor-Receptor in Advanced Non-Melanoma Skin Cancer.
    Wollina U; Tchernev G; Lotti T
    Open Access Maced J Med Sci; 2018 Jan; 6(1):152-155. PubMed ID: 29484016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of unresectable squamous cell carcinoma of the skin with epidermal growth factor receptor antibodies--a case series.
    Eder J; Simonitsch-Klupp I; Trautinger F
    Eur J Dermatol; 2013; 23(5):658-62. PubMed ID: 24135559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacologic treatment options for advanced epithelial skin cancer.
    Soura E; Chasapi V; Stratigos AJ
    Expert Opin Pharmacother; 2015; 16(10):1479-93. PubMed ID: 26027692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The epidermal growth factor receptor in squamous cell carcinoma: An emerging drug target.
    Gaffney DC; Soyer HP; Simpson F
    Australas J Dermatol; 2014 Feb; 55(1):24-34. PubMed ID: 23425099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging Nonsurgical Therapies for Locally Advanced and Metastatic Nonmelanoma Skin Cancer.
    Chen L; Aria AB; Silapunt S; Migden MR
    Dermatol Surg; 2019 Jan; 45(1):1-16. PubMed ID: 30045105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of advanced cutaneous squamous cell carcinomas with epidermal growth factor receptor inhibitors.
    Alter M; Satzger I; Mattern A; Kapp A; Gutzmer R
    Dermatology; 2013; 227(4):289-94. PubMed ID: 24217470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-melanoma skin cancer: new and future synthetic drug treatments.
    Amaral T; Garbe C
    Expert Opin Pharmacother; 2017 May; 18(7):689-699. PubMed ID: 28414587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer.
    Wong SF
    Clin Ther; 2005 Jun; 27(6):684-94. PubMed ID: 16117976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tomotherapy concomitant with cetuximab, followed by cetuximab as single-agent therapy for unresectable squamous cell carcinoma of the skin: a case report.
    Falivene S; Giugliano FM; Grimaldi AM; Di Franco R; Toledo D; Muto M; Cammarota F; Borzillo V; Ascierto PA; Muto P
    BMC Dermatol; 2014 Sep; 14():15. PubMed ID: 25270710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eruptive cutaneous squamous cell carcinoma and psoriasis: response to cetuximab.
    Kamaria M; Shea CR; Chin RK; Cohen EE; Maggiore R; Bolotin D
    Clin Exp Dermatol; 2014 Jul; 39(5):604-7. PubMed ID: 24758726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EGFR targeting drugs in the treatment of head and neck squamous cell carcinoma.
    Sundvall M; Karrila A; Nordberg J; Grénman R; Elenius K
    Expert Opin Emerg Drugs; 2010 Jun; 15(2):185-201. PubMed ID: 20415599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin.
    Maubec E; Petrow P; Scheer-Senyarich I; Duvillard P; Lacroix L; Gelly J; Certain A; Duval X; Crickx B; Buffard V; Basset-Seguin N; Saez P; Duval-Modeste AB; Adamski H; Mansard S; Grange F; Dompmartin A; Faivre S; Mentré F; Avril MF
    J Clin Oncol; 2011 Sep; 29(25):3419-26. PubMed ID: 21810686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update in the treatment of non-melanoma skin cancers: the use of PD-1 inhibitors in basal cell carcinoma and cutaneous squamous-cell carcinoma.
    Ascierto PA; Schadendorf D
    J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36455990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of an EGFR blocker and a COX-2 inhibitor for the treatment of advanced cutaneous squamous cell carcinoma.
    Jalili A; Pinc A; Pieczkowski F; Karlhofer FM; Stingl G; Wagner SN
    J Dtsch Dermatol Ges; 2008 Dec; 6(12):1066-9. PubMed ID: 19138272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An evolving paradigm for the workup and management of high-risk cutaneous squamous cell carcinoma.
    O'Bryan K; Sherman W; Niedt GW; Taback B; Manolidis S; Wang A; Ratner D
    J Am Acad Dermatol; 2013 Oct; 69(4):595-602.e1. PubMed ID: 23871719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New Perspectives in the Pharmacological Treatment of Non-Melanoma Skin Cancer.
    Savoia P; Cremona O; Fava P
    Curr Drug Targets; 2016; 17(3):353-74. PubMed ID: 26245477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cutaneous squamous cell carcinoma responding serially to single-agent cetuximab.
    Suen JK; Bressler L; Shord SS; Warso M; Villano JL
    Anticancer Drugs; 2007 Aug; 18(7):827-9. PubMed ID: 17581306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral therapy for nonmelanoma skin cancer in patients with advanced disease and large tumor burden: a review of the literature with focus on a new generation of targeted therapies.
    Rudnick EW; Thareja S; Cherpelis B
    Int J Dermatol; 2016 Mar; 55(3):249-58; quiz 256, 258. PubMed ID: 26566923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.